美聯新材(300586.SZ):控股子公司鋰電池濕法隔膜產業化建設項目部分生產線試產成功
格隆匯4月5日丨美聯新材(300586.SZ)公佈,此前披露,為進一步抓住新能源的發展機遇,根據國內市場的需求並結合自身發展目標,公司控股子公司安徽美芯新材料有限公司(“美芯新材”)投資新建了鋰電池濕法隔膜產業化建設項目。
截至公吿日,美芯新材完成了兩條雙向拉伸薄膜生產線及配套塗覆產線的建設工作並試產成功,3#-4#產線進入設備安裝階段,其餘生產線也在加快建設中。
鋰電池濕法隔膜產業化建設項目系公司對新能源賽道的重要佈局,此次項目部分生產線試產成功有利於加快項目正式投產,後續對公司盈利能力與經營業績具有一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.